Paul Brennan

Professor Paul Brennan is the Chief Scientific Officer of the Oxford Drug Discovery Institute (ODDI) at the University of Oxford. He joined the ODDI as the Head of Chemistry in 2015. As a highly accomplished medicinal chemist with particular expertise in early drug discovery, he has been instrumental in developing and leading the Institute’s diverse portfolio of drug discovery projects. Paul received his PhD in organic chemistry from UC Berkeley working on combinatorial chemistry and antibiotics. Following post-doctoral research at the University of Cambridge on total synthesis, Paul returned to California to take a position at Amgen. His research was focussed on kinase inhibitors for oncology. After two years at Amgen, Paul moved to Pfizer in Sandwich, UK and, in 2011, joined the Structural Genomics Consortium as Professor of Medicinal Chemistry to discover chemical probes for epigenetic proteins.